NC Medicaid
Pharmacy Prior Approval Request for
Sovaldi

Beneficiary Information

1. Beneficiary Last Name: ___________________________________ 2. First Name: ____
3. Beneficiary ID #: ________________________ 4. Beneficiary Date of Birth: ________________________ 5. Beneficiary Gender: __________

Prescriber Information

6. Prescribing Provider NPI #: ____
7. Requester Contact Information - Name: _________________________________ Phone #: ______________________ Ext. _______________

Drug Information

8. Drug Name: ____________________________________ 9. Strength: _____________________ 10. Quantity Per 30 Days: 28
11. Length of Therapy (in days): ☐ 365 Days

Clinical Information

Total Length of Therapy (Check ONE):

☐ 12 weeks = Genotype 1, 2, or 4 for treatment-naïve and treatment-experienced adult beneficiaries without cirrhosis or with compensated cirrhosis (child-pugh A); or genotype 2 for treatment-naïve and treatment-experienced pediatric patients, 3 years of age or older, without cirrhosis or with compensated cirrhosis (child-pugh A). Genotype 1 and previously treated with a regimen containing an NS3/4A PI2 without prior treatment with an NS5A inhibitor

☐ 24 weeks = Genotype 1 adult beneficiaries that are PEG-interferon ineligible; genotype 3 for treatment-naïve and treatment experienced adults without cirrhosis or with compensated cirrhosis (child-pugh A); or genotype 3 for treatment-naïve and treatment-experienced pediatric patients, 3 years of age or older, without cirrhosis or with compensated cirrhosis (child- pugh A)

☐ 48 weeks = Genotype 1,2,3, or 4 for adult beneficiaries with a diagnosis of Hepatocellular Carcinoma awaiting liver transplantation (up to 48 weeks or until liver transplantation, whichever comes first)

1. What is the beneficiary's Genotype? _________________
2. Is the beneficiary 18 years of age or older with a diagnosis of Chronic Hepatitis C infection with confirmed genotype 1 or 4 without cirrhosis or with compensated cirrhosis? ☐ **Yes** ☐ **No**
3. Is the beneficiary 3 years of age or older with a diagnosis of Chronic Hepatitis C infection with confirmed genotype 2 or 3 without cirrhosis or with compensated cirrhosis? ☐ **Yes** ☐ **No**
4. Does the beneficiary have a CHC infection with hepatocellular carcinoma awaiting a liver transplant? ☐ **Yes** ☐ **No**
5. As the provider, are you reasonably certain that treatment will improve the beneficiary's overall health status? ☐ **Yes** ☐ **No**
6. Is Sovaldi being prescribed in combination with:
   - ☐ Ribavirin and pegylated Interferon alfa for Genotype 1 or 4
   - ☐ Ribavirin for beneficiaries with genotype 1 who are peginterferon-ineligible (medical record documentation of previous peginterferon therapy or reason for ineligibility must be submitted for review)
   - ☐ Ribavirin for Genotypes 2 or 3 and/or in CHC patients with hepatocellular carcinoma awaiting liver transplant
7. Is Sovaldi being used as monotherapy? ☐ **Yes** ☐ **No**
8. Is Sovaldi being used with any other sofosbuvir containing regimen? ☐ **Yes** ☐ **No**
9. Does the beneficiary have FDA labeled contraindication to sofosbuvir (Sovaldi)? ☐ **Yes** ☐ **No**

Fax this form to CSRA at (855) 710-1969 Pharmacy PA Call Center: (866) 246-8505

DHB Pharmacy __

10. Is the beneficiary pregnant? ☐ **Yes** ☐ **No**
11. Does the beneficiary have severe renal impairment (CrCl less than 30mL/min), end stage renal disease, or requires dialysis (AASLD/IDSA 2014)? ☐ **Yes** ☐ **No**
12. Is the beneficiary a non-responder to sofosbuvir? ☐ **Yes** ☐ **No**
13. Has the beneficiary previously failed therapy with a treatment regimen that included sofosbuvir? ☐ **Yes** ☐ **No**
14. Does the beneficiary have hepatocellular carcinoma and is not awaiting liver transplant? ☐ **Yes** ☐ **No**

Signature of Prescriber: ____ Date: __________________________

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.